-
RTSN share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of RTSN shares has decreased $1.47 since the market last closed. This is a 12.25% drop.
-
Closed at $10.53.
The stock has since dropped $0.47 in after-hours trading.
Key terms
About RTSN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
-
Market cap: $82.99M
A market capitalization up to $300 million places RTSN in the micro-capitalization category.
Key terms
Smart score
Latest RTSN news
No recent TipRanks articles are available for RTSN
RTSN Financials
-
RTSN total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
RTSN net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
RTSN earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
RTSN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RTSN Competitors
-
How competitors are chosen
RTSN's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $82.99M
A market capitalization up to $300 million places RTSN in the micro-capitalization category.
